Skip to content
Replidyne logo — Developing groundbreaking anti-infective products through pr...

Replidyne

Developing groundbreaking anti-infective products through proprietary DNA replication technology and strategic in-licensing.

Founded 2000 Series A Total: $13.00M Biopharma, Biotechnology

General Information

Company Name Replidyne
Founded Year 2000
Industries Biopharma, Biotechnology
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Replidyne. To contact Replidyne, visit replidyne.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Replidyne compare?

A PDF of Replidyne and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Replidyne soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Replidyne

Replidyne is a pharmaceutical company specializing in the development and commercialization of innovative anti-infective products. The company, founded in 2000, is focused on developing groundbreaking anti-infective products through proprietary DNA replication technology and strategic in-licensing efforts. Their development pipeline is based on this proprietary DNA replication technology and strategic in-licensing, positioning them as a leader in the Biopharma and Biotechnology industries. In April 2002, Replidyne secured a $13.00M Series A investment from notable investors including HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, and Johnson & Johnson Development Corporation. This investment signifies a strong show of confidence in Replidyne's innovative approach to tackling infectious diseases. The support from these prominent investors further validates Replidyne's potential for growth and success in the biopharmaceutical industry.

Business keywords: pharmaceutical company, anti-infective products, innovation, DNA replication technology, specialty pharmaceuticals, proprietary technology, development pipeline, in-licensing, commercialization, drug development

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $13.00M 4
HealthCare Ventures, Morgenthaler Ventures +2
19 Apr 2002

Replidyne Alternatives & Competitors

View All Alternatives
Replidyne vs

Pioneering pain management with innovative products and advanced abuse prevention technologies

Post-IPO Equity
Biopharma, Biotechnology
Replidyne vs

At DevsHealth, we leverage our advanced DeepTech platform to enhance the development of anti-infecti...

4 employees
AI, Biopharma
Replidyne vs

Innovative solutions driving advancements in cancer treatment through strategic development and comm...

Post-IPO Debt
51-200 employees
Biopharma, Biotechnology

FAQ About Replidyne

Developing groundbreaking anti-infective products through proprietary DNA replication technology and strategic in-licensing.
Replidyne was founded in 2000.
Replidyne operates in Biopharma and Biotechnology. Its work centres on pharmaceutical company, anti-infective products, innovation and DNA replication technology.
Replidyne has completed 1 funding round, raising a total of $13.00M. The latest funding stage is Series A.
Top alternatives and competitors to Replidyne include QRxPharma, DevsHealth, Spectrum Pharmaceuticals, EOC Pharma Group, Eton Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Replidyne and QRxPharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Replidyne, https://www.bouncewatch.com/company/replidyne, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout